Cargando…

Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration

Metabolic diseases are a worldwide health problem. Insulin resistance (IR) is their distinctive hallmark. For their study, animal models that provide reliable information are necessary, permitting the analysis of the cluster of abnormalities that conform to it, its progression, and time-dependent mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarmiento-Ortega, Victor Enrique, Moroni-González, Diana, Diaz, Alfonso, García-González, Miguel Ángel, Brambila, Eduardo, Treviño, Samuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144445/
https://www.ncbi.nlm.nih.gov/pubmed/37110230
http://dx.doi.org/10.3390/metabo13040572
_version_ 1785034101654290432
author Sarmiento-Ortega, Victor Enrique
Moroni-González, Diana
Diaz, Alfonso
García-González, Miguel Ángel
Brambila, Eduardo
Treviño, Samuel
author_facet Sarmiento-Ortega, Victor Enrique
Moroni-González, Diana
Diaz, Alfonso
García-González, Miguel Ángel
Brambila, Eduardo
Treviño, Samuel
author_sort Sarmiento-Ortega, Victor Enrique
collection PubMed
description Metabolic diseases are a worldwide health problem. Insulin resistance (IR) is their distinctive hallmark. For their study, animal models that provide reliable information are necessary, permitting the analysis of the cluster of abnormalities that conform to it, its progression, and time-dependent molecular modifications. We aimed to develop an IR model by exogenous insulin administration. The effective dose of insulin glargine to generate hyperinsulinemia but without hypoglycemia was established. Then, two groups (control and insulin) of male Wistar rats of 100 g weight were formed. The selected dose (4 U/kg) was administered for 15, 30, 45, and 60 days. Zoometry, a glucose tolerance test, insulin response, IR, and the serum lipid profile were assessed. We evaluated insulin signaling, glycogenesis and lipogenesis, redox balance, and inflammation in the liver. Results showed an impairment of glucose tolerance, dyslipidemia, hyperinsulinemia, and peripheral and time-dependent selective IR. At the hepatic level, insulin signaling was impaired, resulting in reduced hepatic glycogen levels and triglyceride accumulation, an increase in the ROS level with MAPK-ERK1/2 response, and mild pro-oxidative microenvironmental sustained by MT, GSH, and GR activity. Hepatic IR coincides with additions in MAPK-p38, NF-κB, and zoometric changes. In conclusion, daily insulin glargine administration generated a progressive IR model. At the hepatic level, the IR was combined with oxidative conditions but without inflammation.
format Online
Article
Text
id pubmed-10144445
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101444452023-04-29 Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration Sarmiento-Ortega, Victor Enrique Moroni-González, Diana Diaz, Alfonso García-González, Miguel Ángel Brambila, Eduardo Treviño, Samuel Metabolites Article Metabolic diseases are a worldwide health problem. Insulin resistance (IR) is their distinctive hallmark. For their study, animal models that provide reliable information are necessary, permitting the analysis of the cluster of abnormalities that conform to it, its progression, and time-dependent molecular modifications. We aimed to develop an IR model by exogenous insulin administration. The effective dose of insulin glargine to generate hyperinsulinemia but without hypoglycemia was established. Then, two groups (control and insulin) of male Wistar rats of 100 g weight were formed. The selected dose (4 U/kg) was administered for 15, 30, 45, and 60 days. Zoometry, a glucose tolerance test, insulin response, IR, and the serum lipid profile were assessed. We evaluated insulin signaling, glycogenesis and lipogenesis, redox balance, and inflammation in the liver. Results showed an impairment of glucose tolerance, dyslipidemia, hyperinsulinemia, and peripheral and time-dependent selective IR. At the hepatic level, insulin signaling was impaired, resulting in reduced hepatic glycogen levels and triglyceride accumulation, an increase in the ROS level with MAPK-ERK1/2 response, and mild pro-oxidative microenvironmental sustained by MT, GSH, and GR activity. Hepatic IR coincides with additions in MAPK-p38, NF-κB, and zoometric changes. In conclusion, daily insulin glargine administration generated a progressive IR model. At the hepatic level, the IR was combined with oxidative conditions but without inflammation. MDPI 2023-04-18 /pmc/articles/PMC10144445/ /pubmed/37110230 http://dx.doi.org/10.3390/metabo13040572 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sarmiento-Ortega, Victor Enrique
Moroni-González, Diana
Diaz, Alfonso
García-González, Miguel Ángel
Brambila, Eduardo
Treviño, Samuel
Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title_full Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title_fullStr Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title_full_unstemmed Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title_short Hepatic Insulin Resistance Model in the Male Wistar Rat Using Exogenous Insulin Glargine Administration
title_sort hepatic insulin resistance model in the male wistar rat using exogenous insulin glargine administration
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10144445/
https://www.ncbi.nlm.nih.gov/pubmed/37110230
http://dx.doi.org/10.3390/metabo13040572
work_keys_str_mv AT sarmientoortegavictorenrique hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration
AT moronigonzalezdiana hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration
AT diazalfonso hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration
AT garciagonzalezmiguelangel hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration
AT brambilaeduardo hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration
AT trevinosamuel hepaticinsulinresistancemodelinthemalewistarratusingexogenousinsulinglargineadministration